Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Amarin (AMRN) is significantly outperforming its medical peers year-to-date, with a 36.6% return compared to the medical sector's average loss of 2.3%; GSK is also outperforming with a 20.8% return. Amarin's positive performance is supported by a 57% increase in its full-year earnings consensus estimate over the past three months, earning it a Zacks Rank #2 (Buy), while GSK's EPS estimate increased 5.3% with the same Zacks Rank.

Analysis

Amarin (AMRN) has demonstrated significant outperformance within the Medical sector year-to-date, delivering a 36.6% return against the sector's average decline of 2.3% and its specific Medical - Biomedical and Genetics industry's 0.6% loss. This robust performance is underscored by a strong positive revision in its earnings outlook, with the Zacks Consensus Estimate for AMRN's full-year earnings increasing by 57% over the past three months, contributing to its Zacks Rank of #2 (Buy). Similarly, GSK, another constituent of the Medical - Biomedical and Genetics industry, has also outperformed, registering a 20.8% year-to-date return, supported by a 5.3% increase in its current year consensus EPS estimate over the same period and also holding a Zacks Rank #2 (Buy). The Medical sector itself holds a Zacks Sector Rank of #6 out of 16, while the Medical - Biomedical and Genetics industry is ranked #78, indicating a mixed broader environment where AMRN and GSK are notable positive outliers. The improving analyst sentiment for both companies, particularly the substantial earnings estimate uplift for AMRN, suggests a strengthening fundamental picture that has likely fueled their respective market outperformance.

Key Decisions for Investors

• Given Amarin's substantial year-to-date outperformance of 36.6% and a significant 57% upward revision in full-year earnings estimates, coupled with a Zacks Rank #2 (Buy), investors might consider this stock for potential further gains, especially as Zacks methodology suggests such stocks may beat the market in the near term.
• Investors should closely monitor whether Amarin and GSK can sustain their positive momentum and analyst sentiment, as their outperformance contrasts with the negative average returns of the broader Medical sector and their specific industry.
• The positive earnings outlook revisions and 'Buy' ratings for both AMRN and GSK suggest they are fundamentally sound choices within their peer group, warranting consideration for inclusion or increased allocation in portfolios focused on the medical sector, though continued vigilance on industry trends is advised.